This Article Full Text Full Text (PDF) All Versions of this Article: 147/1/502    most recent Author Manuscript (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Dumesny, C. Articles by Shulkes, A. Search for Related Content PubMed PubMed Citation Articles by Dumesny, C. Articles by Shulkes, A.

Synthesis, Expression and Biological Activity of the Prohormone for Gastrin Releasing Peptide (ProGRP)

Department of Surgery, Austin Health (C.D., O.P., S.L., G.S.B., A.S.) and Department of Medicine (A.S.G.), Western Hospital, University of Melbourne, Victoria 3084, Australia

Address all correspondence and requests for reprints to: Arthur Shulkes, University of Melbourne, Department of Surgery, Austin Health, Heidelberg, Victoria 3084, Australia. E-mail: aas{at}unimelb.edu.au.

Gastrin-releasing peptide (GRP) has a widespread distribution and multiple stimulating effects on endocrine and exocrine secretions and metabolism. The prohormone for GRP (ProGRP, 125 amino acids) is processed to the amidated, biologically active end products GRP_1–27 and GRP_18–27. Amidated forms of GRP are putative autocrine or paracrine growth factors in a number of cancers including colorectal cancer. However, the potential role and biological activity of proGRP has not been investigated. Using a newly developed antisera directed to the N terminus of human proGRP, proGRP immunoreactivity was detected in all of the endometrial, prostate, and colon cancer cell lines tested and in nine of 10 resected colorectal carcinomas. However, no amidated forms were detected, suggesting an attenuation of processing in tumors. Recombinant proGRP was expressed as a His-tag fusion protein and purified by metal affinity chromatography and HPLC. ProGRP stimulated proliferation of a colon cancer cell line and activated MAPK, but unlike GRP_18–27amide had no effect on inositol phosphate production. ProGRP did not compete with iodinated bombesin in binding assays on Balb-3T3 cells transfected with the known GRP receptors, GRP-R or BRS-3. We conclude that proGRP is present in a number of cancer cell lines and in resected colorectal tumors and is biologically active. Our results suggest that antagonists to GRP precursors rather than the amidated end products should be developed as a treatment for colorectal and other cancers that express proGRP-derived peptides.

This article has been cited by other articles:

				M. S. Nordlund, D. J. Warren, K. Nustad, J. Bjerner, and E. Paus Automated Time-Resolved Immunofluorometric Assay for Progastrin-Releasing Peptide Clin. Chem., May 1, 2008; 54(5): 919 - 922. [Abstract] [Full Text] [PDF]

				R. T. Jensen, J. F. Battey, E. R. Spindel, and R. V. Benya International Union of Pharmacology. LXVIII. Mammalian Bombesin Receptors: Nomenclature, Distribution, Pharmacology, Signaling, and Functions in Normal and Disease States Pharmacol. Rev., March 1, 2008; 60(1): 1 - 42. [Abstract] [Full Text] [PDF]

				O. Patel, C. Dumesny, A. Shulkes, and G. S. Baldwin C-Terminal Fragments of the Gastrin-Releasing Peptide Precursor Stimulate Cell Proliferation via a Novel Receptor Endocrinology, March 1, 2007; 148(3): 1330 - 1339. [Abstract] [Full Text] [PDF]